Equillium Results Presentation Deck
Response to Standard of Care Induction Therapy
Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis:
Data from the Accelerating Medicines Partnership® (AMP) Lupus Network
Response rates at 12, 26 and 52 weeks
13%
16%
71%
Week 12
equillium
ORR
29%
23%
20%
57%
ORR
43%
28%
23%
49%
Week 26
Complete Response: < 0.5 g/g
Partial Response: > 50% reduction UPCR
No Response: < 50% reduction or worsening UPCR
Week 52
ORR
51%
AMP is a public-private partnership between the
NIH, the FDA, pharma and non-profit organizations
The AMP Lupus Nephritis Cohort
• Cross-sectional and longitudinal analyses of responses of
121 patients with lupus nephritis lupus nephritis (~ mean
UPCR 3.2) on SoC at 12, 26 and 52 weeks
●
Patients with LN undergoing kidney biopsy as part of
standard of care with baseline UPCR > 1.0 g/g
The data is representative of a US multicenter multi-
ethnic, real-world experience and consistent with
placebo group in recently conducted clinical trials
Abbreviations: SoC Standard of Care: ORR: overall response rate; ; UPCR: urine protein creatinine ratio
Izmirly et al., Arthritis Rheumatol. 2021; Carlucci et al., Arthritis Rheumatol. 2020
00View entire presentation